Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynein light chain roadblock-type 2 (DYNLRB2) is a non-catalytic accessory component of the cytoplasmic dynein 1 complex, which acts as a motor for retrograde transport of vesicles and organelles along microtubules[2][3][6]. DYNLRB2 is specifically upregulated in testis tissue at the protein level and is indispensable for proper spindle formation during male meiosis I, where it helps maintain the integrity of spindle poles by inhibiting pericentriolar material (PCM) fragmentation and recruiting proteins critical for spindle pole function, such as NuMA[1]. DYNLRB2 binds to the dynein intermediate chain and functions in a tissue-specific manner, with its expression mutually exclusive to its paralog DYNLRB1, which is present in somatic, mitotic cells. Dysregulation or loss of DYNLRB2 in mice leads to arrested meiosis and abnormal spindle formation, highlighting its role in cell division. Disease associations include links to certain syndromes and possible use as a cancer biomarker, but no drugs are specifically known to directly target DYNLRB2[1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynein light chain roadblock-type 2 (DYNLRB2).